Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Breaking News
One person struck by vehicle on Barwell Rd in Raleigh, police on the scene
Breaking News
U.S. Open scores: Here's the leaderboard for the 124th U.S. Open in Pinehurst
Program
On WRAL at 11 : Going out for Fatherâs Day? Where and when temperatures peak during your holiday weekend
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sarepta Therapeutics
(NQ:
SRPT
)
122.84
-2.16 (-1.73%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Sarepta Therapeutics
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Sarepta Therapeutics To Rally Over 53%? Here Are 10 Other Analyst Forecasts For Wednesday
March 01, 2023
Keybanc raised the price target for Ambarella, Inc. (NASDAQ: AMBA) from $95 to $105. Keybanc analyst John Vinh maintained an Overweight rating. Ambarella shares fell 7.1% to $87.61 in pre-market...
Via
Benzinga
Why Reata Pharmaceuticals Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket
March 01, 2023
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) rose 140.8% to $75.06 in pre-market trading after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
March 01, 2023
It's time to start the day with another breakdown of the biggest pre-market stock movers traders need to know about on Wednesday!
Via
InvestorPlace
Novavax Stock Down On Concern Over Whether The Company Can Continue
February 28, 2023
Novavax warns that it may not be able to continue as a company.
Via
Talk Markets
Expert Ratings for Sarepta Therapeutics
February 15, 2023
Via
Benzinga
9 Analysts Have This to Say About Sarepta Therapeutics
January 20, 2023
Via
Benzinga
BTIG Maintains Buy Rating for Sarepta Therapeutics: Here's What You Need To Know
December 22, 2022
Via
Benzinga
Sarepta Therapeutics (SRPT) Q4 2022 Earnings Call Transcript
February 28, 2023
SRPT earnings call for the period ending December 31, 2022.
Via
The Motley Fool
12 Health Care Stocks Moving In Tuesday's After-Market Session
February 28, 2023
Via
Benzinga
Earnings Scheduled For February 28, 2023
February 28, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter.
Via
Benzinga
Analyst Ratings for Sarepta Therapeutics
November 03, 2022
Within the last quarter, Sarepta Therapeutics (NASDAQ:SRPT) has observed the following analyst ratings:
Via
Benzinga
3 Gene Editing Stocks With the Best Long-Term Potential
January 25, 2023
These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space
Via
InvestorPlace
7 Biotech Stocks That Will Make You Rich in 10 Years
January 18, 2023
Although the health innovation space is risky, the opportunities beckon a look at the biotech stocks that will make you rich in 10 years.
Via
InvestorPlace
2 Under-the-Radar Biotech Stocks to Buy in 2023
January 06, 2023
These biotechnology stocks are pushing ahead with promising innovations.
Via
The Motley Fool
2 Top Healthcare Stocks to Buy for the Long Haul
December 09, 2022
These two companies are just getting started.
Via
The Motley Fool
Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review
December 02, 2022
The S&P 500 is fighting for its 200-day, a critical level for the uptrend.
Via
Investor's Business Daily
Sarepta Therapeutics (SRPT) Q3 2022 Earnings Call Transcript
November 03, 2022
SRPT earnings call for the period ending September 30, 2022.
Via
The Motley Fool
7 Analysts Have This to Say About Sarepta Therapeutics
October 13, 2022
Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:SRPT) within the last quarter:
Via
Benzinga
Sarepta Surges As It Nears The Finish Line With A Muscular Dystrophy Gene Therapy
November 28, 2022
Sarepta Therapeutic is nearing the finish line with its Duchenne muscular dystrophy gene therapy.
Via
Investor's Business Daily
3 Unstoppable Stocks That Could Double in 5 Years
October 29, 2022
The opportunities for these innovators are tremendous.
Via
The Motley Fool
2 Under-the-Radar Biotech Stocks to Buy in 2022
October 19, 2022
These two drugmakers are growing in prominence.
Via
The Motley Fool
Apple To $177? Plus This Analyst Slashes PT On Opendoor Technologies By About 71%
October 17, 2022
Morgan Stanley cut Apple Inc. (NASDAQ: AAPL) price target from $180 to $177. Apple shares rose 1.1% to $139.95 in pre-market trading.
Via
Benzinga
PepGen's Duchenne Candidate Has Potential For Greater Exon Skipping Capabilities At Lower Doses Versus Sarepta's Candidate, Says Analyst
September 28, 2022
Via
Benzinga
$6 Million Bet On Sarepta Therapeutics? 3 Stocks Insiders Are Buying
September 16, 2022
Although US stocks closed lower on Thursday, there were a few notable insider trades.
Via
Benzinga
Analyst Ratings for Sarepta Therapeutics
September 08, 2022
Within the last quarter, Sarepta Therapeutics (NASDAQ:SRPT) has observed the following analyst ratings:
Via
Benzinga
FDA Lifts Clinical Hold On Sarepta's Dose-Expansion Part Of Duchenne Trial
September 06, 2022
Via
Benzinga
Earnings Scheduled For November 2, 2022
November 02, 2022
Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for its second quarter.
Via
Benzinga
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
September 15, 2022
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.
Via
Investor's Business Daily
A Biotech's Stock Just Hit Year High. This Analyst Expects It To Jump Another 16%
September 08, 2022
Morgan Stanley raised the price target on Sarepta Therapeutics Inc (NASDAQ: SRPT) with an equal weight rating.
Via
Benzinga
15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, Axsome
August 30, 2022
Not all shares are slowing down alongside the industry group.
Via
Investor's Business Daily
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.